Congress just told insurers: AI cannot deny your care alone. 🔥 The Doctors Not AI Act lands at exactly the right moment. On September 1, 2026, Rep. Greg Landsman of Ohio introduced H.R. 10210, the Doctors Not AI Act. Two Democrats. Two Republicans. Bipartisan from day one, with Reps. Buddy Carter, Kim Schrier, and Tom Barrett as original cosponsors. Referred to three House committees: Energy and Commerce, Ways and Means, and Education and Workforce. That is a serious bill with serious reach. Here is what it would actually do. 🔹 Bar AI systems from issuing or dictating any adverse benefit determination involving clinical judgment. 🔹 Require a licensed health professional to independently review each patient's circumstances before a medical-necessity denial ...

A doctor writes a prescription. The real nightmare starts after. Insurance approval. Prior authorization. Copay assistance paperwork. Specialty pharmacy routing. Most patients never even see this maze. They just wonder why their medication hasn't arrived. Forus is building the infrastructure to make that maze disappear. According to AlleyWatch, the New York-based AI company just closed a $150 million Series C round led by Bain Capital Ventures, reaching a $3 billion valuation. That valuation tripled in roughly four months. The round included Thrive Capital, General Catalyst, Accel, Redpoint, BoxGroup, Pear VC, Vast Ventures, and SV Angel. Total funding now exceeds $300 million. Founder Sahir Jaggi started this company in 2023. Let that sink in for a moment. Three years old. $300 ...

More radiation on top of immunotherapy should help. It didn't. 🎯 The LONESTAR trial just changed how we should think about local consolidative therapy in metastatic NSCLC. For years, the logic seemed airtight. Debulk residual tumor with radiation or surgery after immunotherapy induction, and systemic disease control should follow. It worked in chemo settings. It felt like a natural extension. But according to News-Medical, results presented at the IASLC 2026 World Conference on Lung Cancer told a different story. The LONESTAR framework forces you to ask six questions before adding LCT to dual checkpoint blockade. 1. What induction regimen was used? LONESTAR studied nivolumab plus ipilimumab as the induction backbone. The negative result applies specifically to dual checkpoint blockade, not ...

40,000 Boston residents could lose Medicaid by January 2027. 🚨 And the city is not waiting around to find out what happens next. According to Boston.gov, Mayor Michelle Wu and the Boston Public Health Commission are awarding $3.3 million to 10 community health centers right now, ahead of the surge. The funding comes from the city's last year of American Rescue Plan Act money. Ten centers will each receive $300,000, with an additional $300,000 going to the Massachusetts League of Community Health Centers. The math here is brutal and predictable. MassHealth projects that new federal work and education requirements alone will put around 40,000 Boston residents at risk of losing coverage starting in January 2027. About 40% of those individuals ...

That stat stopped me cold when I read it this week. 🛑 According to xtelligent Healthtech Analytics, a new study published in PLOS Digital Health evaluated all 1,357 AI and machine learning-enabled medical devices cleared by the FDA through December 5, 2025. Here is what the researchers found: 🔹 Only 34 devices (2.5%) were linked to registered prospective trials 🔹 Only 12 (0.9%) posted results from those trials 🔹 Only 12 (0.9%) progressed to peer-reviewed publication 🔹 Only 3 devices (0.2%) were evaluated for patient-centered outcomes like mortality, morbidity, or readmissions And the radiology-specific number is the one I cannot stop thinking about. Radiology accounts for 78% of cleared devices. But only 1% of those devices were linked to prospective ...

Everyone called WISeR a Medicare efficiency win. The records say otherwise. 🚨 This week the Electronic Frontier Foundation dropped approximately 1,000 pages of internal CMS documents showing what is actually happening inside Medicare's AI prior authorization experiment. The findings are damning. According to EFF, the documents show that WISeR, the Wasteful and Inappropriate Service Reduction model, has resulted in widespread delays and denials of care, operational chaos, and reports of patient harm. Let that sink in. This is not advocacy spin. These are CMS's own contracts, internal status reports, and provider complaints, obtained through federal litigation. Here is what the fetched records reveal: 🔹 CMS launched WISeR in January 2026, subjecting seniors in six states to AI-driven prior authorization decisions ...

90 million Americans can now screen for colorectal cancer with a blood draw. 🩸 This is the access story nobody is talking about enough. According to a September 1 announcement via Business Wire, Carelon Healthcare Services will cover Guardant Health's Shield blood test for colorectal cancer screening, effective November 15. Carelon is one of the largest specialty benefits managers in the country, providing medical benefit management to Blue Cross Blue Shield plans across 26 states. That single policy decision pushes total covered lives for Shield to approximately 90 million people, representing 75% of all eligible patients for CRC screening in the United States. Let that sink in. Three out of four eligible Americans can now access this test. 🔹 Shield ...

A hospital CFO in Dallas sits down at his desk on Tuesday morning. 🏥 His balance sheet looks the same as Monday. His Medicaid funding does not. As of September 1, 2026, Texas hospitals are losing $27 million a day in Medicaid reimbursement. According to the Texas Tribune, reporting published by ABC13, the Trump administration has withheld approval for about $9.8 billion in funding tied to three Medicaid programs. The biggest piece is the Comprehensive Hospital Increase Reimbursement Program, known as CHIRP, which helps hospitals cover the gap between what Medicaid pays and what care actually costs. This is not an abstract budget fight. This hits people. 🔹 Four million low-income Texans are enrolled in Medicaid, most of them children. ...

Cancer care just hit a $2B valuation. No hospital built it. A startup built on virtual navigation did. 🎯 Thyme Care raised $125 million in a Series E round this week, pushing its valuation above $2 billion, according to CNBC. That valuation roughly doubled from its Series D less than a year ago. Let that sink in for a second. The round was led by Morgan Health, with participation from Humana, CVS Health Ventures, AlleyCorp, HealthQuest Capital, and a16z Bio + Health. That is not a list of tourist investors. That is a signal. 🔹 $125M raised in Series E 🔹 Valuation now above $2 billion 🔹 Services available to more than 10.5 million people across all 50 U.S. states ...